Hunan Cancer Hospital
🇨🇳China
Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05460481
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05430906
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 223
- Registration Number
- NCT05427617
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy
Completed
- Conditions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05367739
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05326295
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05206656
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT05151549
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 223
- Registration Number
- NCT05079074
Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT05001971
- Locations
- 🇨🇳
Nong Yang, Changsha, Hunan, China
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04974827
- Locations
- 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China
© Copyright 2024. All Rights Reserved by MedPath